Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW

NCT05359874 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped application has been withdrawn

Conditions

Breast Cancer

Interventions

DRUG: Bevacizumab-IRDye800CW

Sponsor

Technical University of Munich